Diligence memo · auto-generated · as of July 3, 2026
Akers Biosciences, Inc.
Akers Biosciences, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Akers Biosciences, Inc. operates in Biotech / Pharma, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Akers Biosciences, Inc. has raised $79M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2024-05-20.
Most recent recorded round closed around 2025-09-02.
Valuation (modeled)modeled
Provath models Akers Biosciences, Inc. at approximately $31M (range $14M–$44M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.38× the median modeled value of Series B Biotech / Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 10 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 2.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 53% of those peers.
Closest niche peers: Inductive Bio, Inc., Wheeler Bio, Inc., Abrexa Pharmaceuticals, Inc., Puna Bio Corp, Arpeggio Biosciences, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.